Want to see SG:569 full AI Analyst Report?
569 Stock Chart & Stats
S$0.09
<S$0.01(2.13%)
At close: 4:00 PM EST
S$0.09
<S$0.01(2.13%)
Day’s Range― - ―
52-Week RangeS$0.07 - S$0.10
Previous CloseN/A
Volume100.00
Average Volume (3M)97.25K
Market Cap
S$37.82M
Enterprise ValueS$78.28M
Total Cash (Recent Filing)S$6.51M
Total Debt (Recent Filing)S$43.91M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.39
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Top-line Recovery (2025 Revenue Rebound)A 44.7% revenue rebound in 2025 shows the business can restore demand and regain sales momentum after a down year. That kind of recovery supports medium-term revenue visibility, helps leverage fixed costs as volumes normalize, and underpins the case for operational recovery if sustained.
Healthy Gross MarginsConsistently high gross margins (~51–55%) indicate structural pricing power or cost-efficient production in the medical-devices offering. Strong unit economics provide a durable buffer against rising operating costs and improve the potential for margin recovery once operating leverage returns.
Sizable Equity Cushion On Balance SheetMaterial equity levels (~S$71–79m) give the company a solvency buffer to withstand near-term earnings volatility. That capital base supports access to financing if needed and reduces immediate liquidation risk, buying management time to restore profitability without dire capital-structure stress.
Bears Say
Shift To Net Losses In 2024–2025Transitioning from multi-year profitability to net losses weakens internal capital generation and undermines return metrics. Persistent losses erode retained earnings, constrain reinvestment in R&D or sales, and increase reliance on external financing or equity issuance to fund growth and operations over the medium term.
Rising Leverage (debt-to-equity ~0.58)Debt-to-equity increasing to ~0.58 signals greater reliance on debt funding, reducing financial flexibility. With profitability weakened, higher leverage raises fixed interest burdens and refinancing risk, limiting capacity to invest and increasing vulnerability to adverse cash-flow swings over the coming months.
Weakened Cash Generation; Negative Free Cash FlowMaterial deterioration in operating cash flow and consecutive negative free cash flow reduce funding available for operations and capex. Weak cash conversion increases dependence on external funding, raises liquidity risk, and constrains the company’s ability to sustain investment or absorb shocks while profitability is being restored.
VicPlas International Ltd. News
569 FAQ
What was VicPlas International Ltd.’s price range in the past 12 months?
VicPlas International Ltd. lowest share price was S$0.07 and its highest was S$0.10 in the past 12 months.
What is VicPlas International Ltd.’s market cap?
VicPlas International Ltd.’s market cap is S$37.82M.
When is VicPlas International Ltd.’s upcoming earnings report date?
VicPlas International Ltd.’s upcoming earnings report date is Sep 25, 2026 which is in 81 days.
How were VicPlas International Ltd.’s earnings last quarter?
VicPlas International Ltd. released its earnings results on Mar 13, 2026. The company reported -S$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.007.
Is VicPlas International Ltd. overvalued?
According to Wall Street analysts VicPlas International Ltd.’s price is currently Overvalued.
Does VicPlas International Ltd. pay dividends?
VicPlas International Ltd. pays a N/A dividend of S$0.004 which represents an annual dividend yield of N/A. See more information on VicPlas International Ltd. dividends here
What is VicPlas International Ltd.’s EPS estimate?
VicPlas International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VicPlas International Ltd. have?
VicPlas International Ltd. has 511,537,700 shares outstanding.
What happened to VicPlas International Ltd.’s price movement after its last earnings report?
VicPlas International Ltd. reported an EPS of -S$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of VicPlas International Ltd.?
Currently, no hedge funds are holding shares in SG:569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VicPlas International Ltd.
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Republic of China, and the United Kingdom. Its piping division focuses on the manufacturing, trading, and distribution of a variety of piping solutions. These systems are utilized for diverse applications such as waste and potable water management in residential, educational, commercial, and industrial settings; conduits for underground electrical and internal building wiring; and data and signal lines for telecommunication providers. Additionally, Vicplas is engaged in the design, development, production, and assembly of both sterile and non-sterile medical devices. The company also offers specialized project design and engineering services. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Technical Analysis
Asiamedic Limited
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―